NELSON PETER JON has a total of 15 patent applications. Its first patent ever was published in 2005. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals and biotechnology are KALEYDE PHARMACEUTICALS AG, BIRDIE BIOPHARMACEUTICALS INC and GRUPO EMPRESARIAL DE PRODUCCIONES BIOFARMACEUTICAS Y QUIMICAS.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 5 | |
#2 | United States | 3 | |
#3 | WIPO (World Intellectual Property Organization) | 2 | |
#4 | Australia | 1 | |
#5 | Brazil | 1 | |
#6 | China | 1 | |
#7 | Hong Kong | 1 | |
#8 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Nelson Peter Jon | 14 |
#2 | Huss Ralf | 8 |
#3 | Jon Nelson Peter | 1 |
#4 | Grone Hermann-Josef | 1 |
#5 | Ralf Huss | 1 |
Publication | Filing date | Title |
---|---|---|
EP2324847A1 | Acceleration of wound healing by a tissue inhibitor of metalloproteinases (TIMP) linked to glycosylphosphatidylinositol (GPI)-anchors | |
EP2143442A1 | Treatment of solid tumors with tissue inhibitors of metalloproteinases(TIMPs) | |
EP1764372A1 | Tissue inhibitor of metalloproteinases (TIMP) linked to glycosylphosphatidylinositol (GPI)-anchors for treatment of cancer |